×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OVID – ovid therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OVID
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
07:00 am
ovid
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
High
Report
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
11/24
07:19 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/18
07:21 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
11/17
08:06 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
11/12
09:26 am
ovid
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/12
08:19 am
ovid
Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M [Seeking Alpha]
Low
Report
Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M [Seeking Alpha]
11/12
07:00 am
ovid
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Low
Report
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
11/10
08:16 am
ovid
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer [Yahoo! Finance]
Medium
Report
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
07:05 am
ovid
Form 10-Q Ovid Therapeutics Inc. For: Sep 30
Low
Report
Form 10-Q Ovid Therapeutics Inc. For: Sep 30
11/12
07:02 am
ovid
Form 8-K Ovid Therapeutics Inc. For: Nov 12
Medium
Report
Form 8-K Ovid Therapeutics Inc. For: Nov 12
11/7
06:07 am
ovid
Form DEF 14A Ovid Therapeutics Inc. For: Dec 11
Low
Report
Form DEF 14A Ovid Therapeutics Inc. For: Dec 11
10/28
06:04 am
ovid
Form PRE 14A Ovid Therapeutics Inc. For: Dec 11
Medium
Report
Form PRE 14A Ovid Therapeutics Inc. For: Dec 11
10/27
05:27 pm
ovid
Form PREM14A Ovid Therapeutics Inc. For: Dec 11
Medium
Report
Form PREM14A Ovid Therapeutics Inc. For: Dec 11
10/3
05:10 pm
ovid
Form 8-K Ovid Therapeutics Inc. For: Oct 02
Low
Report
Form 8-K Ovid Therapeutics Inc. For: Oct 02
9/16
08:01 am
ovid
Form 8-K Ovid Therapeutics Inc. For: Sep 11
High
Report
Form 8-K Ovid Therapeutics Inc. For: Sep 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/24
Form 8-K Ovid Therapeutics Inc. For: Sep 23
25.5%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
TOP News Decliners
3/12
Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-28.1%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: